Live from ASCO 2023 | Ascentage Pharma Releases the First Dataset of Lisaftoclax in WM, Revealing Encouraging Therapeutic Potential

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and...

Related Keywords

Hong Kong ,Rockville ,Western Australia ,Australia ,United States ,Suzhou ,Jiangsu ,China ,American ,Prnewswire Ascentage Pharma ,Sikander Ailamadhi ,Yifan Zhai ,Ascentage Pharma ,American Society Of Clinical Oncology ,Astrazeneca ,China National Medical Products Administration ,National Reimbursement Drug List ,Dana Farber Cancer Institute ,Md Anderson Cancer Center ,Major National ,Poster Presentation ,American Society ,Clinical Oncology ,Annual Meeting ,Principal Investigator ,Chief Medical Officer ,Hematologic Malignancies ,Chronic Lymphocytic ,Main Board ,Stock Exchange ,Hong Kong Limited ,Major National Rd Projects ,Major New Drug Projects ,New Drug Incubator ,Innovative Drug Programs ,Major Project ,Priority Review Designations ,Breakthrough Therapy Designations ,Drug Evaluation ,Reimbursement Drug List ,Orphan Drug Designation ,Fast Track Designation ,Orphan Designation ,Cancer Center ,Mayo Clinic ,